Treatment of chronic hyponatremia: Now we know how, but do we know when or if?

Journal of the American Society of Nephrology

Volumn 21, Issue 4, 2010, Pages 552-555

  Greenberg, Arthur ^a   Lehrich, Ruediger W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; PLACEBO; SODIUM; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

CHRONIC DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURESIS; DRUG APPROVAL; DRUG FATALITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; POLLAKISURIA; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; UNSPECIFIED SIDE EFFECT; URINE OSMOLALITY; XEROSTOMIA;

EID: 77950605104     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010020157     Document Type: Editorial

References (22)

1. Decaux G: Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 110: 582-584, 2001
2. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099-2112, 2006
3. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N: Efficacy and safety of oral conivaptan: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91: 2145-2152, 2006
4. Soupart A, Gross P, Legros JJ, Alfoldi S, Annane D, Heshmati HM, Decaux G: Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with sat-avaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 1: 1154-1160, 2006
5. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouy-ang J, Czerwiec FS, SALTWATER Investigators: Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21: 705-712, 2010
6. Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 37: 182-191, 2003
7. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 297: 1319-1331, 2007
8. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV: Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 290: 2581-2587, 2003
9. Gheorghiade M, Abraham WT, Albert NM, Gattis SW, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC: Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur Heart J 28: 980-988, 2007
10. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA: Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 41: 32-39, 2005
11. Schrier RW: Body water homeostasis: Clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 17: 1820-1832, 2006
12. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH: Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med 120[Suppl 1]: S1-21, 2007
13. Ellison DH, Berl T: Clinical practice: The syndrome of inappropriate antidiuresis. N Engl J Med 356: 2064-2072, 2007
14. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW: Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 96: 413-417, 1982
15. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW: Radioimmunoassay of plasma arginine vasopressin in hy-ponatremic patients with congestive heart failure. N Engl J Med 305: 263-266, 1981
16. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA: Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 19: 764-770, 2008
17. Waikar SS, Mount DB, Curhan GC, Waikar SS, Mount DB, Curhan GC: Mortality after hospitalization with mild, moderate, and severe hypo-natremia. Am J Med 122: 857-865, 2009
18. Sajadieh A, Binici Z, Mouridsen MR, Nielsen OW, Hansen JF, Hau-gaard SB, Sajadieh A, Binici Z, Mouridsen MR, Nielsen OW, Hansen JF, Haugaard SB: Mild hyponatremia carries a poor prognosis in community subjects. Am J Med 122: 679-686, 2009
19. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G: Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119: 71-78, 2006
20. Gankam KF, Andres C, Sattar L, Melot C, Decaux G: Mild hypona-tremia and risk of fracture in the ambulatory elderly. QJM 101: 583-588, 2008
21. Sandhu HS, Gilles E, DeVita MV, Panagopoulos G, Michelis MF, Sandhu HS, Gilles E, DeVita MV, Panagopoulos G, Michelis MF: Hyponatremia associated with large-bone fracture in elderly patients. Int Urol Nephrol 41: 733-737, 2009
22. Verbalis JG, Barsony J, Sugimura Y, Tian Y, Adams DJ, Carter EA, Resnick HE: Hyponatremia-induced osteoporosis. J Bone Miner Res September 14, 2009 [epub ahead of print]